David M. Langenau, PhD

Langenau Lab

“Identifying molecular pathways that drive progression and relapse in pediatric cancer…”


David M. Langenau, PhD

Associate Professor of Pathology, Harvard Medical School
Director, Molecular Pathology Unit, Massachusetts General Hospital
Member, MGH Cancer Center and Center for Regenerative Medicine

Massachusetts General Hospital
Molecular Pathology Unit
149 13th Street, 6th Floor
Charlestown, MA 02129
Phone: 617-643-6508


The Langenau laboratory research focus is to uncover relapse mechanisms in pediatric cancer. Utilizing zebrafish models of T-cell acute lymphoblastic leukemia (T-ALL) and embryonal rhabdomysoarcoma (ERMS), we have undertaken chemical and genetic approaches to identify novel modulators of progression, therapy-resistance, and relapse. 

The First Subspecialized Pathology Service Uncovering progression=associated driver mutations in T-cell acute lymphoblastic leukemia

T-ALL is an aggressive malignancy of thymocytes that affects thousands of children and adults in the United States each year. Recent advancements  in  conventional chemotherapies have improved the five-year survival rate of patients with T-ALL. However, patients with relapse disease are largely unresponsive to additional therapy and have a very poor prognosis. Ultimately, 70% of children and 92% of adults will die of relapse T-ALL, underscoring the clinical imperative for identifying the molecular mechanisms that cause leukemia cells to re-emerge at relapse. Utilizing a novel zebrafish model of relapse T-ALL, large-scale trangenesis platforms, and unbiased bioinformatic approaches, we have uncovered new oncogenic drivers associated with aggression, therapy resistance and relapse. A large subset of these genes exert important roles in regulating human T-ALL proliferation, apoptosis and response to therapy.  Discovering novel relapse-driving oncogenic pathways will likely identify new drug targets for the treatment of T-ALL.

Visualizing and killing cancer stem cells in embryonal rhabdomyosarcoma

ERMS is a common soft-tissue sarcoma of childhood and phenotypically recapitulates fetal muscle development arrested at early stages of differentiation. Microarray and cross-species comparisons of zebrafish, mouse and human ERMS uncovered the finding that the RAS pathway is activated in a majority of ERMS. Building on this discovery, our laboratory has developed a transgenic zebrafish model of kRASG12D-induced ERMS that mimics the molecular underpinnings of human ERMS. We used fluorescent transgenic zebrafish that label ERMS cell subpopulations based on myogenic factor expression to identify functionally distinct classes of tumor cells contained within the ERMS mass. Specifically, the myf5-GFP+ self-renewing cancer stem cell drives continued tumor growth at relapse and is molecularly similar to a non-transformed, activated muscle satellite cell. Building on the dynamic live cell imaging approaches available in the zebrafish ERMS model, our laboratory has undertaken chemical genetic approaches to identify drugs that kill relapse-associated, self-renewing myf5-GFP+ ERMS cells. We are currently assessing a subset of drugs for their ability to regulate growth of human ERMS cells and mouse xenografts.

Read more about the Langenau Lab from the Center for Cancer Research Annual Report and the Pathology Basic Science Research Brochure

Geometric shapes with fluorescense imaging picturesPathology research report


Group Members

John Moore, PhD    Fellow
Madeline Hayes, PhD    Fellow
Alessandra Welker, PhD   Fellow
Qin Tang     PhD candidate
Elaine Garcia     PhD candidate
Karin McCarthy    Lab Manger

Selected Publications

Moore FE, Garcia EG, Lobbardi R, Jain E, Tang Q, Moore JC, Cortes M, Molodtsov A, Kasheta M, Luo CC, Garcia AJ, Mylvaganam R, Yoder JA, Blackburn JS, Sadreyev RI, Ceol CJ, North TE, Langenau DM.  Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish.  J Exp Med.  2016; 213(6):979-92.

Tang Q, Moore JC, Ignatius MS, Tenente IM, Hayes MN, Garcia EG, Torres Yordán N, Bourque C, He S, Blackburn JS, Look AT, Houvras Y, Langenau DM. Imaging tumour cell heterogeneity following cell transplantation into optically clear immune-deficient zebrafish. Nat Commun. 2016; 7:10358.

Tang Q, Abdelfattah NS, Blackburn JS, Moore JC, Martinez SA, Moore FE, Lobbardi R, Tenente IM, Ignatius MS, Berman JN, Liwski RS, Houvras Y, Langenau DM. Optimized cell transplantation using adult rag2 mutant zebrafish. Nature Methods.  2014; 11(8):821-4.

Blackburn JS, Liu S, Wilder JL, Dobrinski KP, Lobbardi R, Moore FE, Martinez SA, Chen EY, Lee C, Langenau DM. Clonal evolution enhances leukemia-propagating cell frequency in T-cell acute lymphoblastic leukemia through AKT/mTORC1 pathway activation. Cancer Cell. 2014; 25(3):366-78.

Chen EY, DeRan M, Ignatius MS, Grandinetti KB, Clagg R, McCarthy K, Lobbardi RM, Brockmann J, Keller C, Wu X, Langenau DM. GSK3 inhibitors induce the canonical WNT/b-catenin pathway to suppress growth and self-renewal in embryonal rhabdomyosarcoma. PNAS. 2014; 111(14):5349-54.

Ignatius MS, Chen E, Elpek NE, Fuller A, Tenente IM, Clagg R, Liu S, Blackburn JS, Linardic CM, Rosenberg A, Nielsen PG, Mempel TR, Langenau DM. In vivo imaging of tumor-propagating cells, regional tumor heterogeneity and dynamic cell movements in embryonal rhabdomyosarcoma.  Cancer Cell. 2012; 21(5):680-93.

Complete Bibliography of David M. Langenau via PubMed


Contact Us

Langenau Laboratory

Massachusetts General Hospital

149 13th Street, #6012Molecular Pathology Unit Charlestown, MA 02129
  • Phone: 617-643-6508
  • Fax: 617-726-5684

Email: dlangenau@partners.org

Back to Top